The 2015 Fierce 15 biotech execs take a bow

FierceBiotech's annual Fierce 15 is out, with thousands of words from our editors on some of the most interesting up-and-coming private biotechs. Here's what some of the companies had to say in their own words.

Alector: "We are developing drug leads against unique, genetically-validated neuro-immune targets through a novel, hypothesis-driven approach to neurodegeneration. We thank FierceBiotech for recognizing the potential of our strategy," said Arnon Rosenthal, co-founder, president and CEO of Alector. Release

Arvinas: "We are thrilled to be selected by FierceBiotech to be among the top private biotech firms globally," Manuel Litchman, president and chief executive officer of Arvinas, said. "This award recognizes the dedication of our employees, our founder, Dr. Craig Crews, and our partners to bring our PROTAC technologies to patients with difficult to treat diseases." Release

CRISPR Therapeutics: "It is an absolute honor to be recognized by FierceBiotech as one of the most exciting and innovative companies within the biotech industry this year," said Dr. Rodger Novak, Chief Executive Officer of CRISPR Therapeutics. "As the impact of CRISPR-Cas9 continues to expand throughout both industry and academia, CRISPR Therapeutics looks to further contribute our extensive experience in the field in order to provide patients suffering from serious diseases with more versatile and easily accessible gene-based medicines." Release

Intellia Therapeutics: "We're honored to be named to the 2015 'Fierce 15' Biotech Companies ranking and be recognized among other companies in the industry," said Nessan Bermingham, CEO and founder of Intellia Therapeutics. "CRISPR/Cas9 is a breakthrough technology that has the potential to cure people living with life-threatening diseases. As a leading gene-editing company, Intellia is highly focused on advancing the science and we are on a critical path to achieving our mission to transform medicine for patients." Release

NGM Bio: "We are honored to be included in the Fierce 15 class of 2015," said William Rieflin, CEO of NGM Bio. "Credit must go to our terrific team of drug hunters who have spent the last 7 years discovering and developing our pipeline of first-in-class biologics, including the four clinical candidates that we are developing to treat a range of serious liver and cardio-metabolic diseases." Release

Padlock Therapeutics: "The entire Padlock team is honored to be among the impressive list of companies chosen by the editors of FierceBiotech to be part of the Fierce 15," said Michael Gilman, founder and CEO at Padlock. "We try to embody the spirit of being 'fierce' every day in our drug discovery research, our business relationships, and in our efforts to develop treatments for those patients suffering from autoimmune diseases." Release

Revolution Medicines: "At Revolution Medicines, we are committed to transforming drug discovery with a product engine that empowers us to redesign nature's diverse, biologically rich and complex products into powerful medicines for patients with serious diseases," said Dr. Mark Goldsmith, president and chief executive officer of Revolution Medicines. "Since the relatively recent launch of Revolution Medicines, we've made strong progress with two high-impact scientific publications by our academic founder, exciting progress in building our product engine and pipeline, as well as several key leadership and board appointments. It is truly an honor that our company's innovative approach and team are validated by this selection as a member of the select 'Fierce 15' class of 2015." Release

SQZ Biotech: "We are thrilled to be recognized alongside such a distinguished cadre of companies all seeking to make a meaningful impact in our respective fields of science," said SQZ co-founder and CEO Armon Sharei. "Our momentum continues towards developing novel cell therapies using our foundational cell engineering platform and we anticipate an extremely exciting year ahead." Release

Surface Oncology: "It's an honor to be recognized by Fierce as one of the promising new companies in the field", says Deltev Biniszkiewicz, President and CEO of Surface. "I am inspired with how far the company has come in such a short time. The preclinical findings are promising and Surface has the potential to have a meaningful impact on patient outcomes." Release

Syros Pharmaceuticals: "We are thrilled to be selected as a Fierce 15 company for our progress in discovering and developing medicines that treat disease at its core with novel approaches to predict patient response," Dr. Nancy Simonian, CEO of Syros. "This recognition is testament to the strong foundation established at Syros based on our world-renowned scientific founders, incredibly talented and dedicated employees and supportive investors and board of directors. We are excited about the next evolution of the company as we bring our first-in-class medicines to patients." Release

Unum Therapeutics: "We are honored to be recognized by FierceBiotech and to be included in such a strong, promising group of Fierce companies," said Chuck Wilson, president and CEO of Unum Therapeutics. "In the past year, we have made significant progress in building our company and bringing our ACTR therapy to patients. We look forward to continuing to advance and expand our pipeline and to realizing the potential of our ACTR therapy in treating patients with hematological and solid tumors." Release

Yumanity Therapeutics: "We are honored to be named to the 2015 Fierce 15 and believe this is a testament to the potential of our approach to transform drug discovery for neurodegenerative diseases caused by protein misfolding," said Dr. Tony Coles, chairman and chief executive officer of Yumanity. Release